Monomers and oligonucleotides comprising cycloaddition adduct(s)
US-9198972-B2 · Dec 1, 2015 · US
Polymer-sunitinib conjugates
US9827326B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9827326-B2 |
| Application number | US-201113996834-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 23, 2011 |
| Priority date | Dec 23, 2010 |
| Publication date | Nov 28, 2017 |
| Grant date | Nov 28, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention relates to (among other things) polymer-sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over sunitinib in unconjugated form.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound encompassed within the formula and pharmaceutically acceptable salts thereof, wherein each n is an integer from about 100 to about 2270. 2. A composition comprising (i) a compound, of claim 1 , and (ii) a pharmaceutically acceptable excipient. 3. The compound of claim 1 , wherein each n is an integer from about 136 to about 2050. 4. The compound of claim 3 , wherein each n is an integer from about 225 to about 1930.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
- A61K47/58Primary
obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin · CPC title
- A61K31/404Primary
Indoles, e.g. pindolol · CPC title
the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9827326B2 cover?
- The invention relates to (among other things) polymer-sunitinib conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over sunitinib in unconjugated form.
- Who is the assignee on this patent?
- Culbertson Sean M, Kozlowski Antoni, Vinson Tony Drew, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K47/58. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Nov 28 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).